EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cefepime-taniborbactam demonstrates potent in vitro activity vs Enterobacterales with bla OXA-48

Maria F Mojica iD, Elise T Zeiser, Scott A Becka, David A Six iD, Greg Moeck iD, Krisztina M Papp-Wallace iD

Microbiology Spectrum · 05.11.2024 · 12 (11)

DOI: 10.1128/spectrum.01144-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 05.11.2024. Verfasst von Maria F Mojica und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Cefepime, Microbial Sensitivity Tests, Anti-Bacterial Agents, beta-Lactamases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: BLRD VA, U.S. Department of Veterans Affairs (VA), U.S. Department of Health and Human Services (HHS).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Taniborbactam (formerly VNRX-5133) is a novel, investigational boronic acid β-lactamase inhibitor. The combination of cefepime (FEP) with taniborbactam is active against Enterobacterales carrying class A, B, C, and/or D enzymes. We assessed the activity of FEP-taniborbactam against Enterobacterales clinical strains carrying bla OXA-48 ( N = 50, 100%), of which 78% harbored at least one extended-spectrum β-lactamase (ESBL). CLSI-based agar dilution susceptibility testing was conducted using FEP-taniborbactam and comparators FEP, meropenem-vaborbactam (MVB), and ceftazidime-avibactam (CZA). The addition of taniborbactam lowered FEP MICs to the provisionally susceptible range of ≤16 µg/mL; the MIC 90 value decreased from ≥64 µg/mL for FEP to 4 µg/mL for FEP-taniborbactam. Notably, FEP-taniborbactam MIC 50 /MIC 90 values (0.5/4 µg/mL) were lower than those for MVB (1/16 µg/mL) and comparable to those for CZA (0.5/1 µg/mL). Time-kill assays with E. coli clinical strains DOV ( bla OXA-48 , bla CTX-M-15 , bla TEM-1 , and bla OXA-1 ) and MLI ( bla OXA-48 , bla VEB , bla TEM-1 , and bla CMY-2 ) revealed that FEP-taniborbactam at concentrations 1×, 2×, and 4× MIC displayed time-dependent reductions in the number of CFU/mL from 0 to 6 h, and at 4× MIC demonstrated bactericidal activity (3 log 10 reduction in CFU/mL at 24 h). Therefore, taniborbactam in combination with FEP was highly active against this diverse panel of Enterobacterales with bla OXA-48 and represents a potential addition to our antibiotic arsenal. IMPORTANCE OXA-48-like β-lactamases are class D carbapenemases widespread in Klebsiella pneumoniae and other Enterobacterales and are associated with carbapenem treatment failures. As up to 80% of OXA-48-like positive isolates coproduce extended-spectrum β-lactamases, a combination of β-lactams with broad-spectrum β-lactamase inhibitors is required to counteract all OXA-48-producing strains effectively. Herein, we evaluated the activity of cefepime-taniborbactam against 50 clinical strains producing OXA-48. We report that adding taniborbactam shifted the minimum inhibitory concentration (MIC) toward cefepime’s susceptible range, restoring its antimicrobial activity. Notably, cefepime-taniborbactam MIC 50 /MIC 90 values (0.5/4 µg/mL) were comparable to ceftazidime-avibactam (0.5/1 µg/mL). Finally, time-kill assays revealed sustained bactericidal activity of cefepime-taniborbactam for up to 24 h. In conclusion, cefepime-taniborbactam will be a welcome addition to the antibiotic arsenal to combat Enterobacterales producing OXA-48.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CefepimeMicrobial Sensitivity TestsAnti-Bacterial Agentsbeta-LactamasesHumansDrug Combinationsbeta-Lactamase InhibitorsAzabicyclo CompoundsBoronic AcidsEnterobacteriaceaeCeftazidimeBacterial ProteinsMeropenemEnterobacteriaceae InfectionsBorinic AcidsCarboxylic AcidsEscherichia coli Proteins

Stichwörter der Autor:innen

EnterobacteralesOXA-48carbapenemasecefepime-taniborbactamβ-lactamβ-lactamase inhibitorβ-lactamases

Substanzen

CefepimeAnti-Bacterial Agentsbeta-LactamasestaniborbactamDrug Combinationsbeta-Lactamase InhibitorsAzabicyclo CompoundsBoronic AcidsCeftazidimeBacterial Proteins

Autor:innen und Institutionen

  • Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA.
  • Research Service, Veterans Affairs Northeast Ohio Healthcare System, Cleveland, Ohio, USA.
  • CASE-VA Center for Antimicrobial Resistance and Epidemiology, Cleveland, Ohio, USA.
  • Grupo de Resistencia Antimicrobiana y Epidemiología Hospitalaria, Universidad El Bosque, Bogotá, Colombia.
  • Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA.
  • Department of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.

ORCID-Profile: Maria F Mojica, David A Six, Greg Moeck, Krisztina M Papp-Wallace

Förderung

  • BLRD VA
  • U.S. Department of Veterans Affairs (VA)
  • U.S. Department of Health and Human Services (HHS)

Zitieren

APA

Mojica, M. F., Zeiser, E. T., Becka, S. A., Six, D. A., Moeck, G., & Papp-Wallace, K. M. (2024). Cefepime-taniborbactam demonstrates potent in vitro activity vs Enterobacterales with bla OXA-48. Microbiology Spectrum, 12(11). https://doi.org/10.1128/spectrum.01144-24

Vancouver

Mojica MF, Zeiser ET, Becka SA, Six DA, Moeck G, Papp-Wallace KM. Cefepime-taniborbactam demonstrates potent in vitro activity vs Enterobacterales with bla OXA-48. Microbiology Spectrum. 2024;12(11). doi:10.1128/spectrum.01144-24

BibTeX
@article{Mojica2024,
  author = {Mojica, Maria F and Zeiser, Elise T and Becka, Scott A and Six, David A and Moeck, Greg and Papp-Wallace, Krisztina M},
  title = {Cefepime-taniborbactam demonstrates potent in vitro activity vs Enterobacterales with bla OXA-48},
  journal = {Microbiology Spectrum},
  year = {2024},
  volume = {12},
  number = {11},
  doi = {10.1128/spectrum.01144-24}
}
Kostenlos starten →